JP7737723B2 - バイオマーカーの組合せ、及び、当該組合せを用いた認知機能障害又はそのリスクの検出方法 - Google Patents

バイオマーカーの組合せ、及び、当該組合せを用いた認知機能障害又はそのリスクの検出方法

Info

Publication number
JP7737723B2
JP7737723B2 JP2022561960A JP2022561960A JP7737723B2 JP 7737723 B2 JP7737723 B2 JP 7737723B2 JP 2022561960 A JP2022561960 A JP 2022561960A JP 2022561960 A JP2022561960 A JP 2022561960A JP 7737723 B2 JP7737723 B2 JP 7737723B2
Authority
JP
Japan
Prior art keywords
cognitive impairment
biomarker
amino acid
biomarkers
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2022561960A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2022102654A1 (https=
Inventor
ひとみ 伊藤
珊 劉
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
MCBI Inc
Original Assignee
MCBI Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by MCBI Inc filed Critical MCBI Inc
Publication of JPWO2022102654A1 publication Critical patent/JPWO2022102654A1/ja
Application granted granted Critical
Publication of JP7737723B2 publication Critical patent/JP7737723B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
    • G16H50/20—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
    • G16H50/30—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indices; for individual health risk assessment
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4709—Amyloid plaque core protein
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4716—Complement proteins, e.g. anaphylatoxin, C3a, C5a
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/775—Apolipopeptides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/50—Determining the risk of developing a disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/56—Staging of a disease; Further complications associated with the disease

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biomedical Technology (AREA)
  • Medical Informatics (AREA)
  • Public Health (AREA)
  • Pathology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Chemical & Material Sciences (AREA)
  • Databases & Information Systems (AREA)
  • Epidemiology (AREA)
  • Data Mining & Analysis (AREA)
  • Primary Health Care (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • General Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
JP2022561960A 2020-11-10 2021-11-10 バイオマーカーの組合せ、及び、当該組合せを用いた認知機能障害又はそのリスクの検出方法 Active JP7737723B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063111796P 2020-11-10 2020-11-10
US63/111,796 2020-11-10
PCT/JP2021/041332 WO2022102654A1 (ja) 2020-11-10 2021-11-10 バイオマーカーの組合せ、及び、当該組合せを用いた認知機能障害又はそのリスクの検出方法

Publications (2)

Publication Number Publication Date
JPWO2022102654A1 JPWO2022102654A1 (https=) 2022-05-19
JP7737723B2 true JP7737723B2 (ja) 2025-09-11

Family

ID=81602278

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022561960A Active JP7737723B2 (ja) 2020-11-10 2021-11-10 バイオマーカーの組合せ、及び、当該組合せを用いた認知機能障害又はそのリスクの検出方法

Country Status (3)

Country Link
US (1) US20250191768A1 (https=)
JP (1) JP7737723B2 (https=)
WO (1) WO2022102654A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4549945A1 (en) * 2022-06-28 2025-05-07 Mcbi Inc. Assessment-supporting information generating method, assessment-supporting information generating system, and information processing device
US20240371497A1 (en) * 2023-05-04 2024-11-07 United Arab Emirates University System and method for diagnostics and finding treatments for mild cognitive impairment, dementias and neurodegenerative diseases

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009016734A1 (ja) 2007-07-31 2009-02-05 University Of Tsukuba 軽度認知機能障害の検定方法
JP2012132808A (ja) 2010-12-22 2012-07-12 Mcbi:Kk 認知機能障害疾患のバイオマーカーおよび該バイオマーカーを用いる認知機能障害疾患の検出方法
WO2014207888A1 (ja) 2013-06-28 2014-12-31 株式会社Ｍｃｂｉ 認知機能障害疾患のバイオマーカー及び当該バイオマーカーを用いる認知機能障害疾患の検出方法
JP2016526167A (ja) 2013-06-07 2016-09-01 エレクトロフォレティクス リミテッド アルツハイマー病に関する物質と方法
WO2019012671A1 (ja) 2017-07-13 2019-01-17 株式会社Ｍｃｂｉ 認知機能障害疾患のバイオマーカーおよび該バイオマーカーを用いる認知機能障害疾患の検出方法

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009016734A1 (ja) 2007-07-31 2009-02-05 University Of Tsukuba 軽度認知機能障害の検定方法
JP2012132808A (ja) 2010-12-22 2012-07-12 Mcbi:Kk 認知機能障害疾患のバイオマーカーおよび該バイオマーカーを用いる認知機能障害疾患の検出方法
JP2016526167A (ja) 2013-06-07 2016-09-01 エレクトロフォレティクス リミテッド アルツハイマー病に関する物質と方法
WO2014207888A1 (ja) 2013-06-28 2014-12-31 株式会社Ｍｃｂｉ 認知機能障害疾患のバイオマーカー及び当該バイオマーカーを用いる認知機能障害疾患の検出方法
WO2019012671A1 (ja) 2017-07-13 2019-01-17 株式会社Ｍｃｂｉ 認知機能障害疾患のバイオマーカーおよび該バイオマーカーを用いる認知機能障害疾患の検出方法

Also Published As

Publication number Publication date
WO2022102654A1 (ja) 2022-05-19
JPWO2022102654A1 (https=) 2022-05-19
US20250191768A1 (en) 2025-06-12

Similar Documents

Publication Publication Date Title
US12399183B2 (en) Biomarkers for cognitive dysfunction diseases and method for detecting cognitive dysfunction disease using biomarkers
JP6012923B2 (ja) 認知機能障害疾患のバイオマーカーおよび該バイオマーカーを用いる認知機能障害疾患の検出方法
JP2010271078A (ja) 認知機能障害疾患を含む精神疾患のバイオマーカーおよび該バイオマーカーを用いた認知機能障害疾患を含む精神疾患の検出方法
JP7737723B2 (ja) バイオマーカーの組合せ、及び、当該組合せを用いた認知機能障害又はそのリスクの検出方法
JP6113798B2 (ja) 認知機能障害疾患のバイオマーカーおよび該バイオマーカーを用いる認知機能障害疾患の検出方法
WO2019012671A1 (ja) 認知機能障害疾患のバイオマーカーおよび該バイオマーカーを用いる認知機能障害疾患の検出方法
JP6967206B2 (ja) 認知機能障害疾患のバイオマーカー及び該バイオマーカーを用いる認知機能障害疾患の検出方法
JP6359158B2 (ja) 認知機能障害疾患のバイオマーカーおよび該バイオマーカーを用いる認知機能障害疾患の検出方法
JP6408087B2 (ja) 認知機能障害疾患のバイオマーカーおよび該バイオマーカーを用いる認知機能障害疾患の検出方法
JP6359160B2 (ja) 認知機能障害疾患のバイオマーカーおよび該バイオマーカーを用いる認知機能障害疾患の検出方法
JP6193942B2 (ja) 認知機能障害疾患のバイオマーカーおよび該バイオマーカーを用いる認知機能障害疾患の検出方法
JP6359159B2 (ja) 認知機能障害疾患のバイオマーカーおよび該バイオマーカーを用いる認知機能障害疾患の検出方法

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240820

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250617

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250725

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20250812

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20250825

R150 Certificate of patent or registration of utility model

Ref document number: 7737723

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150